Search Results
Your search for ,SeT matches 2078 pages
Showing 801 - 850Optimizing Metabolic Discoveries
Obesity is a leading cause of cancer, and researchers are working to learn more about the biology behind the body’s metabolism and the promotion of cancer growth. “While we know that physical activity and a balanced diet are generally healthy, we don’t yet have the data to make personalized...
Motivating Yourself for Exercise Goals in the New Year
The day after Christmas, I walked into the exercise studio and spent the next hour jogging, rowing, and doing exactly what that morning’s coach instructed the 20 or so participants of the class to do next. The hour passed quickly, and I had little or no time to think about anything other than the...
2020 GI Cancers Symposium: Detecting GI Tumors Using a Cell-Free DNA Test
A blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal (GI) cancers could potentially help detect disease at earlier stages. This research will be presented by Brian M. Wolpin, MD, MPH, and colleagues at the 2020 Gastrointestinal Cancers...
FDA Pipeline: Priority Reviews in Ovarian Cancer, Prostate Cancer, and NSCLC
This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for ovarian, prostate, and lung cancer; granted Orphan Drug designation to therapies for chemotherapy-induced thrombocytopenia and multiple myeloma; and granted Breakthrough Device designation to platforms...
Selected Abstracts on Novel Therapies for Chronic Myeloid Leukemia
To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens for chronic myeloid leukemia (CML). For full details of...
Transplantation Specialist Karen Ballen, MD, Treasures Long-Term Connections With Her Patients
Karen Ballen, MD, an international expert in stem cell transplantation, particularly for patients who have a difficult time finding a donor, was born and reared in the Bronx in a family that encouraged academic and professional pursuits. “My grandfather was an old-fashioned pediatrician who made...
One Cycle of Bleomycin/Etoposide/Cisplatin May Be as Effective as Two for Patients With Testicular Cancer
Testicular cancer recurrence may be prevented by giving men one cycle of chemotherapy instead of the two cycles used as standard. Lowering the overall exposure to chemotherapy also reduced side effects. These findings were published by Cullen et al in European Urology. Testicular cancer is the most ...
FDA Finalizes Enforcement Policy on Unauthorized Flavored Cartridge-Based E-Cigarettes
Amid the epidemic levels of youth use of e-cigarettes and the popularity of certain products among children, the U.S. Food and Drug Administration (FDA) has issued a policy prioritizing enforcement against certain unauthorized flavored e-cigarette products that appeal to children, including fruit...
ASCO and IASLC Collaborate to Improve the Quality of Lung Cancer Care in Brazil
Medical oncologists in Brazil are being encouraged to take advantage of a new measure set for assessing the quality of care they provide to patients with lung cancer. Lung cancer is one of the most prevalent and deadly types of cancer in Brazil.1 Providing a platform for health-care providers to...
Time to Treatment Is a Priority
Dr. Smith called us on a Tuesday afternoon. “I have a patient who has an abnormal mammogram showing a large mass. I’m suspecting cancer and am referring her to you for diagnosis and treatment. She’s very anxious. I hope you can help.” We were able to get Dr. Smith’s patient in the next day for...
FDA Pipeline: Priority Reviews in SCLC, Bladder Cancer, Colorectal Cancer
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Reviews for treatments in extensive-stage small cell lung cancer (SCLC), non–muscle invasive bladder cancer, and BRAF V600E–mutant colorectal cancer. The Agency also recently issued multiple Breakthrough Therapy designations and ...
Incidence of Squamous Cell Carcinoma of the Anus Has ‘Increased Dramatically’ in Older Women and Young Black Men
“Squamous cell carcinoma of the anus incidence has increased dramatically in elderly women and young black men,” according to a study of recent trends in incidence and mortality. “Advanced-stage [anal squamous cell carcinoma] incidence tripled with a prominent rise in … mortality,” researchers...
ASCO/NCODA Release Standards for Medically Integrated Dispensing of Oral Anticancer Drugs
ASCO and the National Community Oncology Dispensing Association (NCODA) have published recommended standards for medically integrated dispensing of oral anticancer therapies and supportive care medications in the oncology clinic.1 “The NCODA created quality standards 6 years ago and recognized the ...
Rising Cost and Use of Oral Anticancer Drugs and Increased Medicare Part D Spending
In a study reported in a research letter in JAMA Oncology, Emily Stamell Ruiz, MD, MPH, and colleagues found that rising drug costs and use accounted for 56% and 44%, respectively, of increased Medicare Part D spending on oral anticancer drugs between 2013 and 2017. Study Details The analysis...
A Systematic Approach to Identifying the Molecular Factors That Lead to Cancer Progression
Although gene mutations are the primary drivers of carcinogenesis, an array of complex and tumor-specific molecular interaction networks determine cancer cell behavior. To learn more about this line of inquiry, The ASCO Post recently spoke with Andrea Califano, Dr., Professor of Chemical Biology...
Stephen Hahn, MD, Confirmed as FDA Commissioner by Senate
On December 12, the United States Senate voted 72–18 to confirm Stephen Hahn, MD, as Commissioner of the U.S. Food and Drug Administration (FDA). A radiation oncologist, Dr. Hahn was previously the Chief Medical Executive and Gilbert H. Fletcher Distinguished Memorial Chair and Professor of...
SABCS 2019: Postoperative S-1 Plus Endocrine Therapy for HR-Positive, HER2-Negative Breast Cancer
The postoperative combination of S-1, an oral fluoropyrimidine-based drug, with endocrine therapy improved invasive disease–free survival and 5-year invasive disease–free survival estimates in patients with hormone receptor (HR)-positive, HER2-negative breast cancer, according to results from the...
ASH Recognized Choosing Wisely Champions at 2019 Annual Meeting & Exposition
The American Society of Hematology (ASH) recognized three Choosing Wisely® Champions, practitioners working to tackle the overuse of hematology tests and treatments, at its 2019 Annual Meeting & Exposition in Orlando: Stephen L. Wang, MD, of Kaiser Permanente Santa Clara Medical Center, Santa...
ASH 2019: Genomic Features of AML in Patients Aged 60 or Older May Predict Stem Cell Transplant Outcome
For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of leukemic genetic characteristics, according to results presented by Murdock et al at the 2019 American Society of Hematology (ASH) Annual...
Checkpoint Inhibitor Pneumonitis: A Pulmonologist’s Perspective
Oncologists have become accustomed to seeing pneumonitis associated with immune checkpoint inhibitor treatment in non–small cell lung cancer (NSCLC), requiring intervention by pulmonologists in the management of severe cases. At CHEST 2019, the annual meeting of the American College of Chest...
Despite Challenges, Pioneer in CT Screening for Early Lung Cancer Works to Move the Field Forward
In 1999, a team of researchers from Weill Cornell Medical College advocated the use of a then-novel practice: low-dose radiation CT screening for lung cancer. It captures a full thoracic image in a single breath hold, and can recognize a tumor in its earliest stages when the chance for cure is...
Oncology Massage Therapy for Chemotherapy-Induced Peripheral Neuropathy
Oncology massage therapy might be a helping hand for patients suffering from chronic chemotherapy-induced peripheral neuropathy, according to data presented at the 2019 Supportive Care in Oncology Symposium.1 The results of the pilot study supported the premise that patients who received massages...
A Need for Human Connection Led to a Rewarding Career in Geriatric Oncology for Lodovico Balducci, MD
Older adults are the fastest-growing segment of our population, and more than 65% of patients with newly diagnosed cancer are 65 years of age or older. Although we now recognize the special needs of older patients with cancer, the field of geriatric oncology emerged quietly, with early growing...
Expert Point of View: Marleen Kok, MD
“This is currently the largest data set with information on retreatment,” said formal study discussant Marleen Kok, MD, of the Netherlands Cancer Institute, Amsterdam, The Netherlands. She noted there was a partial response in 11% and stable disease in 60%. “Upon initial treatment, partial...
Study Finds Durvalumab Retreatment Active in Some Patients With Advanced Solid Tumors
Immunotherapy with checkpoint inhibitors offers a proportion of patients a chance at long-term disease control, resembling cure in some patients. Among the many questions about immunotherapy that remain to be resolved is whether patients who discontinue therapy and develop progressive disease can...
Addressing the Obesity Epidemic and Barriers to Implementing Weight Management Programs for Cancer Survivors
Earlier this year, ASCO published the results of its new study on oncologists’ perceptions and practice behaviors regarding obesity, weight management, and related lifestyle factors in their patients both during and after cancer treatment.1 The findings from the online survey of 971 oncology...
Affirming Universal Health Care as a Fundamental Human Right
This year’s meeting of the World Cancer Leaders’ Summit: Cancer and Universal Health Coverage, held on October 15–17 in Nur-Sultan, Kazakhstan, brought together more than 350 global health leaders, including ministers of health, first ladies, and industry leaders, from 82 countries to discuss how...
Confirmation Hearing for FDA Commissioner Nominee Stephen Hahn, MD
On November 20, 2019, Stephen Hahn, MD, President Trump’s nominee to be the next Commissioner of the U.S. Food and Drug Administration (FDA), appeared before the Senate Health, Education, Labor, and Pension Committee and answered wide-ranging questions relating to the many important roles the...
Challenging the Global Community to Deliver Equitable Cancer Care for All
For Her Royal Highness Princess Dina Mired of Jordan, ensuring that every patient with cancer receives high-quality care is not an abstract goal—it is personal. Princess Dina saw firsthand the life-and-death differences that access to state-of-the-art oncology care makes in a patient’s life when...
Machine Learning Algorithm for Genome-Derived Prediction of Tumor Type
In a study reported in JAMA Oncology, Penson et al developed a machine learning algorithmic classifier that may be successful in identifying tumor type and origin based on DNA-sequence data obtained at point of care. The study used machine learning to construct and train an algorithmic classifier...
Disparities in Culturally Competent Cancer Care
Many nonwhite minority cancer survivors place importance on seeing doctors who share or understand their culture, but are less likely than non-Hispanic whites to be able to see such physicians, according to a new study. The study, which is one of the first nationally-representative studies to...
ESMO Congress 2019: Quick Takes From Key Clinical Trials
The ESMO Congress continues to grow as a pivotal platform for research in clinical oncology. At the ESMO Congress 2019, important findings were showcased in more than 2,200 studies, including 93 late-breaking abstracts. The ASCO Post summarized much of that news in separate articles over several...
New JCO CCI Article Discusses Difficulties in Gathering Real-World Evidence
A new JCO Clinical Cancer Informatics (JCO CCI) article highlights the challenges in—and need for—obtaining real-world evidence for assessing the effectiveness of precision medicine on areas such as survival, quality of life, cost, and health disparities. The paper, titled “Clinical Molecular...
The Oncology Care Model and Quality of Care: Defining, Measuring, and Implementing New Approaches to Cancer Care
The Oncology Care Model was instituted in 2016 by the Center for Medicare & Medicaid Innovation as a move away from the fee-for-service payment model and toward value-based care. It has sparked discussion ever since. How should quality be defined? Whose and what values should it reflect? How...
AACR Project GENIE Begins 5-Year Collaborative Research Project With $36 Million in New Funding
The American Association for Cancer Research (AACR) initiative known as AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) is launching a 5-year, $36 million research collaboration with a coalition of nine biopharmaceutical companies. The goal of the project is to obtain clinical ...
2019 NCRI: CA125 Testing May Help General Practitioners to Detect Ovarian Cancer
Testing for levels of the serum biomarker cancer antigen 125 (CA125) in the blood may be a useful tool for the detection of ovarian cancer, and could help detect other types of cancer among patients in primary care, according to research presented by Funston et al at the 2019 National Cancer...
Machine-Learning Model May Predict Unplanned Hospitalizations After Radiation Therapy for Gastrointestinal Cancer
Unplanned hospitalizations may be common among patients with cancer, but they diminish quality of care while racking up high costs for patients and the health-care system alike. According to data presented at the 2019 ASCO Quality Care Symposium, however, a new predictive model may help providers...
An Early Love of Nature’s Biodiversity Leads to a Career in Cancer Research for Lisa Coussens, PhD
Founded in 1887, the Oregon Health Sciences University (OHSU) is located in Portland, Oregon, and is home to the cutting-edge Coussens Lab, which focuses on the role of immune cells and their mediators as critical regulators of cancer development. The lab’s eponymous Director, Lisa Coussens, PhD,...
Expert Point of View: Thomas Powles, MD, PhD
In metastatic urothelial carcinoma, the bar has been set low, with a median survival of 1 year in cisplatin-eligible patients and 6 to 8 months when platinum-based therapy fails to elicit a response in patients, explained formal study discussant Thomas Powles, MD, PhD, Director, Bart’s Cancer...
Study Finds Nearly One in Four Oncologists Rarely or Never Mention Cost When Discussing Genomic Testing
Nearly one in four oncologists report rarely or never discussing the costs of genomic testing with their patients, according to a new study led by American Cancer Society investigators. The study, published by Yabroff et al in the Journal of the National Cancer Institute, found that oncologists...
ASCO National Cancer Opinion Survey: Cancer Prevention, E-Cigarette, and End-of-Life Knowledge Gaps Reported
One in four Americans say they incorporate cancer prevention into their daily lives, according to ASCO’s third annual National Cancer Opinion Survey, despite research showing that as many as half of all cancer cases are preventable. The survey found low levels of awareness of known cancer risk...
FDA Pipeline: Treatments for HER2-Positive Breast Cancer, AML; Breakthrough Device for Prostate Cancer; Statement on Safety Information for Breast Implants
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to trastuzumab deruxtecan for the treatment of HER2-positive metastatic breast cancer; granted Fast Track designation for bemcentinib for elderly patients with relapsed acute myeloid leukemia (AML); granted Breakthrough...
POLE/POLD1 Mutations and Outcomes With Immune Checkpoint Inhibitor Therapy
In a research letter published in JAMA Oncology, Feng Wang, MD, PhD, and colleagues identified the frequency of mutations in DNA polymerase epsilon (POLE) and delta 1 (POLD1) genes across cancer types and found that these mutations were associated with better survival outcomes among patients...
The Art of Medicine: Our Role as Patient Advocates
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Cancer Researcher Mary J.C. Hendrix, PhD, Returns to West Virginia to Lead Her Alma Mater
Nationally regarded melanoma researcher Mary J.C. Hendrix, PhD, was born in La Jolla, California, a seaside community surrounded by ocean bluffs and beaches within the city of San Diego. She was reared in a Navy family that moved from the West Coast to the East Coast during her childhood,...
ASCO Breakthrough: Breast Cancer Gene-Expression Signature May Help Predict Recurrence Postradiotherapy
Researchers have identified a gene pattern that may help predict which patients with breast cancer will have early or late disease recurrence following radiation therapy. The ability to predict the timing of recurrence could change—and improve—treatment strategies and determine the length of...
Reflecting on My First National Presentation
I gave my first national presentation of my original clinical research on a topic that was to become a professional obsession: finding a cure for esophageal cancer. (Spoiler, I failed.) It was late May 1982. Writing about this now is undoubtedly predicated on my recent retirement, my desire to...
FDA Pipeline: Advances in Prostate Cancer, Urothelial Cancer, Myelofibrosis, and More
In the past few weeks, the U.S. Food and Drug Administration (FDA) has issued regulatory decisions in prostate cancer, urothelial cancer, myelofibrosis, breast cancer, pediatric brain cancer, leukemia, and skin cancer. Breakthrough Therapy Designation for Niraparib in Metastatic...
Selpercatinib: Precision Medicine for RET Fusion–Positive NSCLC
Selpercatinib (LOXO-292), a RET kinase inhibitor, demonstrated antitumor activity in the lungs and brain and durable responses with acceptable tolerability in patients with RET fusion–positive non–small cell lung cancer (NSCLC), according to an updated analysis of the LIBRETTO-001 registration...
ESMO 2019: Personalized Treatment for Head and Neck Cancer Based on Geriatric Assessment
Fit elderly patients aged 70 years and older with head and neck squamous cell carcinoma were able to undergo rigorous treatment that provided benefit similar to that observed in younger patients. However, elderly patients with head and neck squamous cell carcinoma classified by geriatric assessment ...
